Inventor · disambiguated record
Brian Elliott
Also filed as: ELLIOTT BRIAN · ELLIOTT BRIAN W
8 granted patents·10 pending applications·92 citations·filing 1985–2023
87Inventor score
Top patents by PatentIndex Score
18 records- 0196US11608383B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Mar 21, 2023·8 cites·30 claims
- 0296US11535679B2Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Granted Dec 27, 2022·8 cites·27 claims
- 0395US11845805B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Dec 19, 2023·5 cites·33 claims
- 0495US11548952B2Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphomaGENMAB AS·Filed 2021·Granted Jan 10, 2023·7 cites·27 claims
- 0593US11858995B2Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Granted Jan 2, 2024·4 cites·28 claims
- 0685US4678712ACurable coating composition and epoxy resin adduct useful thereinDOW CHEMICAL CO·Filed 1985·Granted Jul 7, 1987·36 cites·5 claims
- 0778US12435154B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2021·Granted Oct 7, 2025·1 cites·29 claims
- 0878US2024301078A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2023·Application pending·0 cites
- 0977US4722981AEpoxy resins of controlled conversion and a process for their preparationDOW CHEMICAL CO·Filed 1987·Granted Feb 2, 1988·23 cites·24 claims
- 1068US2024034812A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1166US2024174761A1Bispecific antibodies against cd3 and cd20 for treating richter's syndromeGENMAB AS·Filed 2023·Application pending·0 cites
- 1265US2022112309A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1364US2023355753A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1463US2025304689A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2023·Application pending·0 cites
- 1563US2023312758A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1663US2023357440A1Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
- 1761US2023312757A1Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemiaGENMAB AS·Filed 2021·Application pending·0 cites
- 1857US2023312759A1Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphomaGENMAB AS·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian Elliott files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →